Amplitude Ventures

Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeutic and commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.

DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine or clinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions. Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.

Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients. The company is a group of scientists, technologists, computational biologists, clinicians, and drug hunters who use single-cell genomics and machine learning analysis to find new drugs. Celsius Therapeutics was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.

Gandeeva Therapeutics is a precision biotechnology company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva’s structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline targeting difficult-to-treat cancers with novel protein interaction modulators such as interfacial glues (iGlues™) and allosteric inhibitors. Gandeeva is headquartered in the Greater Vancouver area, Canada. Please visit www.gandeeva.com or follow us on LinkedIn and Twitter for more information.

Valence Discovery is building the world’s most powerful chemistry engine. The company has pioneered the application of few-shot learning in drug design, along with the development of best-in-class AI methods for molecular representation, structure and ligand-based de novo design, and multiparameter optimization, enabling the design of novel chemistry against previously intractable biology.

Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. The company was founded in 2018 and is based in Israel, the Netherlands, and Boston.

Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventricular arrhythmias. Click below to learn more about our programs.

Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.

Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.

Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells. The company's proprietary T-cell production platform enables precision control of Notch signaling, which is required for T-cell development, by combining sophisticated product design with commercial-compatible processes. The ability to control notch signaling eliminates several critical limiting factors in cell therapy development and provides the ability to design and manufacture a consistent and limitless supply of therapeutic T cells. Notch Therapeutics was established in 2018 and is headquartered in Toronto, Canada.

Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.

Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases. Zymeworks' approach combines proprietary molecular modeling and simulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization. It was founded in 2004 and headquartered in Vancouver, British Columbia.

Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.

Shoebox develops validated iPad audiometers to help solve everyday problems faced by hearing health professionals and workplace safety managers. They offer solutions for occupational hearing testing. They offer validated online hearing screening, boothless diagnostic audiometers, and a comprehensive tele-audiology solution.

Imagia's mission is to leverage advances in artificial intelligence and accelerate the advent of accessible personalized medicine. The company's platform leverage advances in artificial intelligence to provide outcome-based structured clinical data and federated learning capabilities across multiple sources while preserving privacy, enabling clinicians to drive end-to-end discoveries of predictive, diagnostic, and prescriptive analytics.

The PHEMI Trustworthy Health DataLab is a unique, cloud-based, integrated big data management system that allows healthcare organizations to enhance innovation and generate value from healthcare data by simplifying the ingestion and de-identification of data with NSA/military-grade governance, privacy, and security built-in.